Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 180
- Registration Number
- NCT01409499
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 35
- Registration Number
- NCT01405573
- Locations
- 🇮🇹
Ospedale Cardarelli, Napoli, Italy
🇮🇹Istituto Oncologico Veneto, Padova, Italy
🇮🇹A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01398501
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2016-09-12
- Target Recruit Count
- 18
- Registration Number
- NCT01376453
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Prof. Dr. med. Max. E. Scheulen
- Target Recruit Count
- 200
- Registration Number
- NCT01377025
- Locations
- 🇩🇪
Universitätsmedizin Berlin, Charité Campus Benjamin Franklin, Berlin, Germany
🇩🇪Universitätsklinikum Erlangen, Erlangen, Germany
🇩🇪Univesitätsklinikum Essen, Essen, Germany
Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 160
- Registration Number
- NCT01357486
- Locations
- 🇫🇷
CHU Le Bocage, Dijon, France
🇫🇷CHU de Nantes Hôpital de l'Hotel Dieu, Nantes, France
🇫🇷CH d'Abbeville, Abbeville, France
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 5
- Registration Number
- NCT01348503
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Centro di Riferimento Oncologico - Aviano
- Target Recruit Count
- 4
- Registration Number
- NCT01342627
- Locations
- 🇮🇹
Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01308723
Sorafenib and TRC105 in Hepatocellular Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT01306058
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.